AB0685 Oxygenated hemoglobin as prognostic marker among patients with systemic sclerosis screened for pulmonary hypertension
Authors: P. Xanthouli, O. Gordjani, C. Eichstaedt, N. Benjamin, F. Trudzinski, B. Egenlauf, S. Harutyunova, A. Marra, N. Milde, C. Nagel, N. Blank, H. M. Lorenz, E. Grünig
Journal: Annals of the Rheumatic Diseases (2022)

Background Oxygenated hemoglobin (OxyHem) 1 in arterial blood may reflect disease severity in patients with systemic sclerosis (SSc), particularly among those with pulmonary manifestations such as pulmonary hypertension (PH). Objectives Hence, the aim of this study was to analyze the predictive value of OxyHem in SSc patients screened for PH. Methods SSc patients were screened for PH including right heart catheterisation, laboratory and clinical assessment. They were followed for 3.2±2.6 (median 3.0) years. OxyHem was measured by multiplying the concentration of hemoglobin with oxygen saturation assessed in arterialized capillary blood. Kaplan-Meier analysis was performed using the defined threshold from Receiver Operating characteristic. Prognostic power was compared with known parameters of prognostic significance in SSc using uni- and multivariable analysis. Clinical parameters of patients with high and low OxyHem were compared by student’s t-test. Results A total of 280 SSc patients were screened, 267 were included in the analysis (82% female, 59.8±13.4 years, 73.8% limited cutaneous SSc), 56 patients had manifest PH and 112 interstitial lung disease (ILD). Low OxyHem ≤12.5g/dl at baseline was significantly associated with a worse survival (p=0.046) among SSc patients. In the multivariable analysis the presence of ILD, age ≥60 years and diffusion capacity (DLCO) ≤65% were associated with worse survival among SSc patients. The combination of low DLCO and low OxyHem at baseline could predict the development of early pulmonary vascular disease at follow- up (sensitivity 79.6%). Conclusion This study detected for the first time that an OxyHem level ≤12.5 g/dl is a prognostic predictor in SSc- patients. Further studies are needed to confirm these results. References [1]Trudzinski, F. C., R. A. Jörres, P. Alter, K. Kahnert, B. Waschki, C. Herr, C. Kellerer, A. Omlor, C. F. Vogelmeier, S. Fähndrich, H. Watz, T. Welte, B. Jany, S. Söhler, F. Biertz, F. Herth, H. U. Kauczor and R. Bals (2020). “Associations of oxygenated hemoglobin with disease burden and prognosis in stable COPD: Results from COSYCONET.” Sci Rep 10 (1): 10544. Disclosure of Interests Panagiota Xanthouli Speakers bureau: MSD and OMT, outside the submitted work, Ojan Gordjani: None declared, Christina Eichstaedt: None declared, Nicola Benjamin Speakers bureau: Actelion pharmaceuticals, Bayer HealthCare and MSD outside the submitted work, Franziska Trudzinski: None declared, Benjamin Egenlauf Speakers bureau: Actelion, MSD, Bayer and OMT outside the submitted work, Satenik Harutyunova Speakers bureau: Bayer, MSD, Actelion and GSK, outside the submitted work., Alberto Marra Speakers bureau: Bayer/MSD outside the submitted work, Nicklas Milde: None declared, Christian Nagel Speakers bureau: from Actelion, MSD, Boehringer, Novartis, Bayer, and AstraZeneca outside the submitted work, Norbert Blank Speakers bureau: MSD, GSK, Actelion and Bayer Vital outside the submitted work, Hanns-Martin Lorenz Speakers bureau: AbbVie, BMS, Pfizer, Cellgene, Medac, GSK, Roche, Chugai, Novartis, UCB, Janssen-Cilag, AstraZeneca, and Lilly (less than $10,000 each) and research support from AbbVie, MSD, BMS, Cellgene, Medac, GSK, Roche, Chugai, Novartis, UCB, Janssen-Cilag, AstraZeneca, Lilly, Baxter, SOBI, Biogen, Actelion, Bayer Vital, Shire, Octapharm, Sanofi, Hexal, Mundipharm, and Thermo Fisher outside the submitted work, Consultant of: AbbVie, BMS, Pfizer, Cellgene, Medac, GSK, Roche, Chugai, Novartis, UCB, Janssen-Cilag, AstraZeneca, and Lilly (less than $10,000 each) and research support from AbbVie, MSD, BMS, Cellgene, Medac, GSK, Roche, Chugai, Novartis, UCB, Janssen-Cilag, AstraZeneca, Lilly, Baxter, SOBI, Biogen, Actelion, Bayer Vital, Shire, Octapharm, Sanofi, Hexal, Mundipharm, and Thermo Fisher outside the submitted work, Ekkehard Grünig Speakers bureau: Actelion, Bayer AG, and MSD; grants from GSK, Novartis, and United Therapeutics; and personal fees from SCOPE, OrPha Swiss GmbH, and Zurich Heart House (less than $10,000 each) outside the submitted work., Consultant of: Actelion, Bayer AG, and MSD; grants from GSK, Novartis, and United Therapeutics; and personal fees from SCOPE, OrPha Swiss GmbH, and Zurich Heart House (less than $10,000 each).